A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Rosiglitazone (BRL49653C)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00432679

AVD105248

Details and patient eligibility

About

This study was designed to compare the efficacy and safety of BRL49653C versus placebo with concomitant use of sulfonyl urea (SU).

Enrollment: 149 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes mellitus managed by SU will be candidate for this study. These candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function.

Exclusion criteria

• Patient with serious cardiovascular disease or serious hepatic disease will not be eligible.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

149 participants in 1 patient group

arm 1

Experimental group

Description:

study drug

Treatment:

Drug: Rosiglitazone (BRL49653C)